ArticleScientific reports2026
Metabotropic glutamate receptor 5 expression associates with pain and inflammatory pathways in interstitial cystitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Interstitial cystitis (IC)/bladder pain syndrome (BPS) is a chronic condition with severe pelvic pain and urinary symptoms significantly impairing quality of life. This study investigated the clinical relevance of the metabotropic glutamate receptor (mGluR) family in IC/BPS. Bladder biopsy samples were taken from 61 patients, including 42 Hunner-type IC, 11 non-Hunner type IC, and 8 controls without IC. Gene expression analysis revealed that mGluR2, mGluR3, and mGluR5 were significantly elevated in patients with IC/BPS compared to controls. Among these, mGluR5 showed the strongest association with pain severity, fibrosis, and lymphoplasmacytic infiltration. Patients with Hunner-type IC also exhibited increased expression of p65 and interleukin-1β, suggesting activation of inflammatory response modulation in IC/BPS. These findings suggest that mGluR5 may contribute to pain through immune response modulation in IC/BPS. Targeting mGluR5 could represent a promising therapeutic strategy to alleviate symptoms and improve patient quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.